In this multicentre, double-blind study, patients with LUTS/BPH were randomised to 26 weeks with finasteride 5 mg once daily (n ¼ 204) or tamsulosin 0.4 mg once daily (n ¼ 199). Double-blind treatment was continued for another 26 weeks (total treatment duration: 1 y). The primary efficacy parameter was the difference in mean change in total Symptom Problem Index (SPI) from baseline to end point at week-26 in the intention-to-treat (ITT) and per protocol (PP) populations. Tamsulosin induced a greater improvement in total SPI (À5.2 points or À37%) compared to finasteride (À4.5 points or À31%) at week-26 (P ¼ 0.055 in ITT and P ¼ 0.032 in PP). Tamsulosin improved urinary symptoms (particularly the more bothersome storage symptoms) and flow more quickly than finasteride. The difference was statistically significant for the SPI from week-1 (reduction, respectively, À2.5 vs À1.8 points, P ¼ 0.043) to week-18 and for Q max from week-1 (increase, respectively, 2.3 vs 0.7 ml/s, P ¼ 0.0007) to week-12. Both treatments were well tolerated with a comparable incidence of adverse events, including urinary retention.